Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let the daytraders do what they do. Us long-term holders will be rewarded greatly in the end.
NNRX isn't on the list.
Those debt don't look like toxic to me. The company can ask for an extension. The new CEO will address that in the upcoming updates.
So the CEO has to increase revenues to $1.3M in order to get extra $100K in salary for the next 3 months. I'm all for it and I'm sure he can do it because he's an expert in this space.
The proposed R/S ratio was either 1 for 5; or 1 for 10; or 1 for 15. Even if they decided to go ahead with the R/S, I don't think it will matter much because the ratio is so low. Plus the current O/S is only 460M. That's too low to do a R/S.
News could come out as soon as Monday. I love the quiet buying.
I view it as an opportunity to take shares from them. Once they're done, people will have to pay higher for shares.
I'm holding a big position and looking to double it when the time comes.
Exactly. You don't find this type of company in the OTC everyday. This is a well established company with great products and well known customers. Now add the potential $$40,000,000 in annual recurring revenue in South Korea. The company's profit margin is 65%. That's unheard of even with the big board companies.
Assets = $4,834,375
Liabilities = $1,181,432
--------------------------
Total stockholders’ equity = $3,390,468
O/S = 52,000,000
Share price at $.01
Market Cap = $520,000 (7 times below Equity)
This market represents a potential annual recurring revenue of $40,000,000 for Ambicom.
This isn't a one-time deal. It's annual recurring revenue of $40,000,000.
Up 50% with only 1M in volume. Imagine if we have 10M in volume.
Game changing news will come out within sometimes next week. That's when the kaboom will start. In the mean time, continue to collect shares down here if folks want to give them up.
Big buys coming in. 625K smack.
Real company with great products and customers. Profit margin is %65. That's top notch and not many companies can achieve this.
All we need is a good group of strong traders, then this will reach penny within a week.
PC Bangs, Internet Cafes, PC Gaming places are very popular in Asia.
Why is PC Bang so popular in Korea?
AmbiCom Holdings Enters PC Bangs Optimization Market in South Korea
MILPITAS, CA--(Marketwired - Sep 30, 2015) - AmbiCom Holdings, Inc. (OTCQB: ABHI), the leading provider of cloud based Active Optimization services for Personal Computers and servers, has entered the South Korean market of PC Bangs.
PC Bangs are LAN based gaming centers where patrons can play multiplayer computer games for an hourly fee. These PC Bangs (or PC rooms) are very popular with students and professionals that want a gaming experience that is separate from normal computer use. There are approximately 10,000 PC Bangs located in South Korea, with an average of 100 high speed workstations in each location. This market represents a potential annual recurring revenue of $40,000,000 for Ambicom.
Initial testing has shown that the Active Optimization software was able to improve network transfer speed of a South Korean based workstation by 50X, making the gaming experience much more effective for the player.
"We believe that a PC Bang operator can offer his customers a superior gaming experience with workstations that have been optimized. As well, optimization can extend the life of a workstation reducing the capital cost invested by the PC Bang operation," stated H.S. Lee, President of Asian markets for Ambicom and previously President and country manager for Intel Korea.
"We are always looking for niche markets for our Active Optimization software where we can improve use experience while improving return on investment for the purchaser. PC Bangs clearly fits this criteria," stated Kevin Cornell, President of Ambicom Holdings, Inc.
About Veloxum Performance Tuning Software
Veloxum actively and continuously optimizes physical and virtual infrastructure by optimizing operating system and application settings. It leverages the existing systems and infrastructure by tuning the various components within their manufacturer supported settings. The solution enables IT organizations to maximize performance, increase workload density, and minimize virtualization costs, ultimately spending less on the physical infrastructure, thus dramatically reducing CAPEX and OPEX expenditure.
Customers such as Watermark Industries, Baron Funds, Colgate Palmolive, Integrated Axis, Deutsche Bank, the United States Department of Energy, and Maimonides Medical Center are enjoying significant cost savings with Veloxum. Veloxum was founded in September, 2007 and was awarded the Gartner "Cool Vendor" award in 2012 in the category of infrastructure management.
About AmbiCom Holdings, Inc.
AmbiCom is headquartered in Milpitas, California, and was a leading designer and developer of innovative wireless hardware more than one million devices sold worldwide. Now it is focusing on tuning software products optimizing complex IT environments, servers, and personal computers. AmbiCom believes there are unique opportunities as a result of the sheer size of the IT, server, and PC marketplace and the Company's innovative approach and exemplary customer services. For more information, visit www.ambicom.com.
Assets = $4,834,375
Liabilities = $1,181,432
--------------------------
Total stockholders’ equity = $3,390,468
O/S = 52,000,000
Share price at $.01
Market Cap = $520,000 (7 times below Equity)
AmbiCom Retires Convertible Debt Vehicle
MILPITAS, CA--(Marketwired - Oct 8, 2015) - AmbiCom Holdings, Inc. (OTCQB: ABHI), the leading provider of cloud based Active Optimization services for Personal Computers and servers has retired a convertible debt vehicle ahead of schedule.
On October 7th, Ambicom retired a note from KBM Worldwide/Vis Vires Group, by paying all principal and accumulated interest. The note amount was $90,000.
"By paying off this note we were able to remove the dilutive effect of the conversion to shares," stated Ambicom Chief Executive Officer John Hwang. "We are seeing strong demand for our products and that allows us to execute on business decisions like this one that is in the best interests of our shareholders."
About Veloxum Performance Tuning Software
Veloxum actively and continuously optimizes physical and virtual infrastructure by optimizing operating system and application settings. It leverages the existing systems and infrastructure by tuning the various components within their manufacturer supported settings. The solution enables IT organizations to maximize performance, increase workload density, and minimize virtualization costs, ultimately spending less on the physical infrastructure, thus dramatically reducing CAPEX and OPEX expenditure.
Customers such as Watermark Industries, Baron Funds, Colgate Palmolive, Integrated Axis, Deutsche Bank, the United States Department of Energy, and Maimonides Medical Center are enjoying significant cost savings with Veloxum. Veloxum was founded in September, 2007 and was awarded the Gartner "Cool Vendor" award in 2012 in the category of infrastructure management.
About AmbiCom Holdings, Inc.
AmbiCom is headquartered in Milpitas, California, and was a leading designer and developer of innovative wireless hardware more than one million devices sold worldwide. Now it is focusing on tuning software products optimizing complex IT environments, servers, and personal computers. AmbiCom believes there are unique opportunities as a result of the sheer size of the IT, server, and PC marketplace and the Company's innovative approach and exemplary customer services. For more information, visit www.ambicom.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited to our ability to maintain our website and associated computer systems, our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one of more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts
J.J. Hwang
AmbiCom Holdings Inc.
(408) 321-0822 x301
jj@ambicom.com
Tom Nelson
TEN Associates LLC
(480) 326-8577
Worthy of a sticky.
Hi linkvest, could you please sticky this post? TIA.
To lock up the entire 400M OS, we only need:
20 investors each holding 20M average.
40 investors each holding 10M average.
80 investors each holding 5M average.
There are currently 134 followers on NNRX. This tells me many investors are keeping NNRX on their watch list. Once they decide to buy in, the OS can easily be locked up.
Profit margin was 50%. That's unheard of in the OTC.
Dr. Edward Eyring Appointed to Chief Executive Officer of Nutranomics
Outgoing CEO, Michael Doron, Supports Eyring's Appointment to Provide Greater On-Site Management of Nutranomics Product and Distribution Development; Dr. Eyring Also Assumes CFO Role to Quantify Pricing and Costing Inefficiencies and Rebuild Sales Network of Nutranomics(R)-Branded Products
DRAPER, UT -- (Marketwired) -- 10/07/15 -- Nutranomics, Inc. (OTC PINK: NNRX) ("Nutranomics" or "The Company"), a diversified nutraceutical formulator, supplement manufacturer and marketer of Nutranomics® health supplements, today announced the appointment of Dr. Edward "Joe" Eyring, past Board certified surgeon and healthcare entrepreneur, to assume CEO responsibilities from Mr. Michael Doron. Neither the Company nor Mr. Doron have cited any issues between parties, and Mr. Doron aided in the recruitment, review and transition of his role to Dr. Eyring.
Dr. Eyring is assuming executive roles and responsibilities as CEO, CFO and President of Nutranomics, Inc., and his appointment was approved by Nutranomics' Chairman of the Board and Founder, Dr. Tracy Gibbs. "As a founder, it is healthy to realize when the expertise in your field of study is greater than your ability to manage a high-growth business and its operations in that same field," began Dr. Gibbs. "This realization prompted us to search for a new CEO in 2014. We are grateful to Michael Doron who provided us valuable insight to acquisition opportunities worldwide; however, we realized that the ability to leverage the value of these acquisitions is based on the continuing strength of our brand and our sales network, which, after many years of fast-paced growth, required revitalization and daily oversight. Having Joe here, full-time, to lead the Company by example, to re-cost current and future products, to reinvigorate a distribution network committed to Nutranomics® and to provide the medical insight to formulate new products is a combination of skills we deem essential at this point in our development."
Edward "Joe" Eyring, II, M.D., 48, is a previous Board-certified colorectal surgeon and successful entrepreneur in the healthcare industry. Dr. Eyring's work in medicine predates his entrance to medical school in the 1980s. His experience in working for naturopathic doctors and an apprenticeship with his father, an orthopedic surgeon himself, who volunteered his expertise to treat orphaned children in developing countries, is credited by Dr. Eyring as the reason for his study of medicine and commitment to healthcare.
Dr. Eyring obtained a BA in Political Science from Emory University and graduated the University of Tennessee Health Science Center College of Medicine in 1994. He completed his internship and residency at the University of Utah School of Medicine in Salt Lake City in 1999, and a fellowship at Ferguson Clinic, Grand Rapids MI, in 2000. During 13 years as a colorectal surgeon, Dr. Eyring helped hundreds of patients survive the effects of colon cancer in the greater Salt Lake City area and has been a Board Member of the American Cancer Society, Utah, for the past 12 years.
As a healthcare entrepreneur, Dr. Eyring gained first-hand knowledge of how rate structures impacted health outcomes; as those without insurance either went into debt or without treatment altogether. This disparity strengthened his resolve to bridge the gap in coverage and provide equal opportunity for anyone to maintain good health. Since 2014, Dr. Eyring has been Managing Director of Domaine Global, LLC. which owns and manages an on-line marketing, fulfillment and customer service platform, NutreaLife®. NutreaLife®'s website and system provide branding and distribution for small to medium-sized nutraceutical companies. From 2010-2013, Dr. Eyring was the Founder, CEO and Chair of Simplify Rx, Inc., a startup company providing patients and doctors in-office dispensing and MTM/clinical pharmacology to facilitate and reduce prescription administration and costs. In 2013, Dr. Eyring served as a Medical Director at Aeromedical Collection Services after which time in 2014, Dr. Eyring founded American Recovery Company, which he has operated until the present date. American Recovery, Inc. helps employers evaluate ERISA law for self-funded employers, prepare for DOL audits, and facilitate reimbursement processing, rates and times for plan holders and employers. From 2004-2013, Dr. Eyring was the founding partner and Medical Director of Physicians Pharmaceutical Services; from 2005-2012, Dr. Eyring was the owner and principal researcher of Synergies Medical Research, LLC; from 2000-2013, Dr. Eyring was a surgeon and Founding Practice Leader at Integrative GI Healthcare, LC; and from 2000-2012, Dr. Eyring was the sole proprietor of the Pelvic Floor Diagnostic Center in Murray, Utah.
"I am fortunate to have the trust of Tracy and support of Michael," began Dr. Joe Eyring, newly-appointed CEO, CFO and President of Nutranomics, Inc. "This is clearly a critical junction for the Company and for our shareholders who have remained steadfast during a difficult time for Nutranomics. As part of my three-month evaluation of the Company's needs, I am certain there is a combination of financial and strategic plans we can implement to reposition Nutranomics in the market and regain the growth momentum characteristic of our past."
The Company and Dr. Eyring have committed to issuing a Shareholder Letter in the next 10 business day to update shareholders on and before October 17, 2015. The Shareholder Letter and update will provide more detail on Company strategies, plans for the immediate and near terms, future growth opportunities and also address shareholder questions recently received by the Company. The letter will be provided in press on financial wires and sent to shareholders who have provided electronic mail addresses to the Company.
About Nutranomics Inc.
Nutranomics, Inc. (OTC PINK: NNRX) has been at the forefront of research and development of nutritional food products since its inception in 1995. In the first years of its operations, Nutranomics provided research and development of supplement formulations and nutraceuticals for domestic and international brands. After developing 100's of successful formulations and patents, Nutranomics developed its own brand of nutraceuticals in 1997, Nurtranomics®, and began to market and sell its products directly to consumers and into retail outlets. Nutranomics maintains customers in the US, Canada, Taiwan, Japan, Singapore, Malaysia, Korea and Poland.
More than just a health supplement manufacturer, Nutranomics supports the worldwide community of people aiming for a healthy lifestyle by making education a core business philosophy.
Forward-Looking Statements:
Safe Harbor: This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Nutranomics Inc., to be materially different from the statements made herein.
Investor relations contact:
John Mattio
Lamnia International for:
Nutranomics, Inc.
Main: +1 (203) 885-1058
Email: jmattio@lamniaintl.com
Source: Nutranomics Inc.
News Link
I don't think it's high risk even if they do go ahead with the R/S because the ratio is so low. The ratio is 1 for between 5 to 15. That's nothing compared to the other stocks in the OTC where the typical R/S is 1 for 1000.
I think the new CEO will not even bother to do it because the O/S is only at 390 million shares. That's way too low for a R/S.
Lots of news will be coming out once the new CEO gets the handle on the company.
Once the bids are 7s and 8s move to 10s and 11s, the asks at 12s will fall quick.
With 390M OS, the MC is only $390K. That's even lower than NNRX's quarterly revenues. It's way undervalue here.
With a few more days like this, the float can easily be locked. That's when the real push up will begin.
Since last Friday and including today, there have been over 200 million shares traded (Friday=50M, Monday=70M, today=90M so far). The float is only 300M.
I agree.
Once investors starts looking into CRGP's Financial Reports, they will find out how undervalued this is.
Even without today's news, CRGP cash on hand was $6.7 million as of last Quarter. That alone is worth .055 per share.
$6,700,000 / 120,000,000 (OS) = .055 per share.
Now add $14.6 million (today's news) on top of that.
$21,000,000 / 120,000,000 (OS) = .175 per share.
I meant today's news hasn't been posted on the Ihub Newswire feed yet. Once that happens, thousands of investors will see it.
Today's news hasn't been posted on IHUB yet.
The Jovita Mine and immediately surrounding area has the following resource estimate:
Non 43-101 compliant based upon management testing
Inclusive of pending mining claims to increase Jovita property footprint from it current 250 hectares to 2,800 hectares (approx.)
45 million tonnes of ore
Average grade of 0.80 lbs per tonne (cut-off grade of 0.2 lbs per tonne)
36,000,000 tonnes or 792,000,000 lbs. Cu.
Contract processing ore purchasing
CRGP to purchase high grade ore from regional artisan mines
Minimum grade of 2% per tonne
Average cost per lb. Cu is $1
CRGP has contract agreements in place to secure high grade feedstock
The initial 250 hectare parcel is currently viewed to contain the following assumptions:
70,875,000 lbs of copper concentrate for every 250 hectares
Net revenue per 250 hectares sector of approximately $3.20-$1.10=2.10 *70,875,000= $141,750,000 USD
$14,600,000 / 120,000,000 (OS) = .12 / share.
Dead money here. People who bought T2 yesterday have the last chance to sell their shares at T2 for the break even before this thing goes to no bid.
I'm here because I look forward into the future and not dwell in the past.
So I take it that you can't name one company that makes money in the OTC?
Show us one (just one) company that makes money in the OTC.
Hemp and Drone? What a perfect combination. Watch out for the fall!